{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:21:36Z","timestamp":1769034096203,"version":"3.49.0"},"reference-count":26,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/duiu3310","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:02:18Z","timestamp":1767682938000},"page":"5349-5363","source":"Crossref","is-referenced-by-count":0,"title":["Novel therapeutic agents and intensive chemotherapy improve survival outcomes in patients with mantle cell lymphoma"],"prefix":"10.62347","volume":"15","author":[{"given":"Zi-Chi","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-00855-9","article-title":"Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group","volume":"13","author":"Yoon","year":"2020","unstructured":"Yoon DH, Cao J, Chen TY, Izutsu K, Kim SJ, Kwong YL, Lin TY, Thye LS, Xu B, Yang DH and Kim WS. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol 2020; 13: 21.","journal-title":"J Hematol Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: a British society for haematology guideline","volume":"204","author":"TA","year":"2024","unstructured":"Eyre TA, Bishton MJ, McCulloch R, O’Reilly M, Sanderson R, Menon G, Iyengar S, Lewis D, Lambert J, Linton KM and McKay P; Haemato-Oncology Task Force of the British Society for Haematology. Diagnosis and management of mantle cell lymphoma: a British society for haematology guideline. Br J Haematol 2024; 204: 108-126.","journal-title":"Br J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1182\/blood.2023022352","article-title":"Frontline management of mantle cell lymphoma","volume":"145","author":"CE","year":"2025","unstructured":"Ryan CE, Armand P and LaCasce AS. Frontline management of mantle cell lymphoma. Blood 2025; 145: 663-672.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Silkenstedt E and Dreyling M. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches. Hematol Oncol 2023; 41 Suppl 1: 36-42.","DOI":"10.1002\/hon.3149"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W and Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","unstructured":"Jain P and Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 2022; 97: 638-656.","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E and Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-3068.","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M and Hiddemann W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M and Hiddemann W. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","unstructured":"Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J and Introna M. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"RI","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O’Connor OA, Shi H, Boral AL and Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H and Cavalli F; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944-953.","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","unstructured":"Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S and Cavalli F; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19: 1449-1458.","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M and Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Zoellner AK, Unterhalt M, Stilgenbauer S, Hubel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, Bouabdallah K, Krauter J, Lenz G, Durig J, Vergote V, Schafer-Eckart K, Andre M, Kluin-Nelemans HC, van Hoof A, Klapper W, Hiddemann W, Dreyling M and Hoster E; European Mantle Cell Lymphoma Network. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2021; 8: e648-e657.","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hanel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Duhrsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M and Dreyling M; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388: 565-575.","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell lymphoma network","volume":"41","author":"Hermine","year":"2023","unstructured":"Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hubel K, Haioun C, Casasnovas RO, Schmidt C, Bouabdallah K, Ribrag V, Kanz L, Durig J, Metzner B, Sibon D, Cheminant M, Burroni B, Klapper W, Hiddemann W, Unterhalt M, Hoster E and Dreyling M; European Mantle Cell Lymphoma Network. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European mantle cell lymphoma network. J Clin Oncol 2023; 41: 479-484.","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Gouill S","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Du K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Bene MC, Salles G, Tilly H, Lamy T, Gressin R and Hermine O; LYSA Group. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017; 377: 1250-1260.","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1182\/bloodadvances.2022007371","article-title":"Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma","volume":"6","author":"Villa","year":"2022","unstructured":"Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Rimsza LM, Ramsower CA, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH and Dreyling M. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. Blood Adv 2022; 6: 5285-5294.","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/bloodadvances.2023009744","article-title":"Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL","volume":"7","author":"Tisi","year":"2023","unstructured":"Tisi MC, Moia R, Patti C, Evangelista A, Ferrero S, Spina M, Tani M, Botto B, Celli M, Puccini B, Cencini E, Di Rocco A, Chini C, Ghiggi C, Zambello R, Zanni M, Sciarra R, Bruna R, Ferrante M, Pileri SA, Quaglia FM, Stelitano C, Re A, Volpetti S, Zilioli VR, Arcari A, Merli F and Visco C. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL. Blood Adv 2023; 7: 3916-3924.","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","unstructured":"Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A and Salles G. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol 2023; 41: 541-554.","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gine E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppa S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hanel M, Dierlamm J, Pott C, Klapper W, Gozel D, Schmidt C, Unterhalt M, Ladetto M and Hoster E. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 2024; 403: 2293-2306.","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1080\/10428194.2023.2227748","article-title":"Treatment of older patients with mantle cell lymphoma in the era of novel agents","volume":"64","author":"Rozental","year":"2023","unstructured":"Rozental A, Jim HSL and Extermann M. Treatment of older patients with mantle cell lymphoma in the era of novel agents. Leuk Lymphoma 2023; 64: 1514-1526.","journal-title":"Leuk Lymphoma"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/sj.bjc.6604201","article-title":"Clinical pharmacology of cancer therapies in older adults","volume":"98","author":"Hurria","year":"2008","unstructured":"Hurria A and Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer 2008; 98: 517-522.","journal-title":"Br J Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"ML","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S and Dreyling M; SHINE Investigators. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022; 386: 2482-2494.","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","unstructured":"Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S and Dreyling M; ECHO investigators; ECHO Investigators. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol 2025; 43: 2276-2284.","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:35:57Z","timestamp":1768977357000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/12\/ajcr0169489.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/duiu3310","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}